Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

• Published in: Leukemia research Vol. 38; no. 1; pp. 10 - 20
• Main Authors: Soverini, Simona, Branford, Susan, Nicolini, Franck E., Talpaz, Moshe, Deininger, Michael W.N., Martinelli, Giovanni, Müller, Martin C., Radich, Jerald P., Shah, Neil P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2014
• Subjects: BCR-ABL1; Chronic myeloid leukemia; DNA Mutational Analysis - methods; DNA Mutational Analysis - trends; Drug Resistance, Neoplasm - genetics; Forecasting; Fusion Proteins, bcr-abl - genetics; Hematology, Oncology and Palliative Medicine; Humans; Kinase domain; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Mutation; Mutations; Philadelphia chromosome; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Resistance; Tyrosine kinase inhibitors; Resistance; Mutations; BCR-ABL1; Kinase domain; Chronic myeloid leukemia; Tyrosine kinase inhibitors; Philadelphia chromosome

Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and th...